Updated
Updated · CNBC · Jun 8Nurix Therapeutics Surges 24% on Roche Deal for Bexobrutideg Cancer, Autoimmune Drug
3 articles · Updated · CNBC · Jun 8Summary
- Nurix Therapeutics jumped 24% in premarket trading after announcing a collaboration with Roche to develop and commercialize bexobrutideg.
- Bexobrutideg is a protein degrader being advanced for cancers and autoimmune diseases, giving Nurix a major pharma partner for the program.
- The move made Nurix one of the biggest prebell gainers, outpacing other notable risers including Marvell Technology, up nearly 9%, and Micron, up 7%.
- The rally highlights how biotech stocks can reprice sharply when drug candidates secure large-partner backing and a clearer commercialization path.
Insights
Nurix secured a massive deal, but can its novel cancer drug overcome the resistance that plagues current treatments? With both Honeywell and Flex spinning off core units, is the era of the diversified tech conglomerate officially over? As Nvidia builds its global 'AI factories,' can the world's energy grids actually support this massive new power demand?